Lou Sehl

Dr. Lou Sehl has over 30 years of experience in the biotechnology, pharmaceutical and medical device industries with a consistent track record of success moving projects through all phases of development. Prior to Evommune, he was vice president of manufacturing and technical operations for MyoKardia, acquired by BMS in late 2020, where he led CMC efforts for multiple clinical development programs, including managing CMC relationships with Sanofi during a four-year partnership. His efforts were instrumental in the successful NDA filing for mavacamten (CamzyosTM). Prior to MyoKardia, Dr. Sehl served as vice president of product development at Medicines360 where he was responsible for drug, device and non-clinical development and supply chain activities. He has also held leadership positions in R&D at Proteolix, Cohesion Technologies, Cor Therapeutics and Genentech and has contributed to 5 IND, 3 IDE, 3 PMA and 3 NDA filings. He earned a PhD in Biochemistry from the University of Notre Dame and a BA in Chemistry from Carthage College.